top of page

£30 million initiative for early-stage antimicrobial innovation


Innovate UK joins forces with LifeArc and Medicines Discovery Catapult to accelerate early-stage innovation in antimicrobial resistance (AMR).


Innovate UK and medical research organisation LifeArc, have each invested £15 million in PACE (Pathways to Antimicrobial Clinical Efficacy), which will be delivered by Medicines Discovery Catapult.

PACE will focus on removing barriers and connecting the AMR ecosystem to accelerate and strengthen the pre-clinical AMR pipeline.

The initiative aims to establish a platform for UK-based early-stage research and development (R&D) projects in medicine discovery and diagnostics, making them more attractive for investment and readily available for medical treatments.


Comments


Other Science, engineering & technology news

bottom of page